Back to results
US 2023/0058425 A1Published application
Crystal form of pyridopyrimidine derivative and preparation method thereof
AssigneesJiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
InventorsQi WU, Zhenxing DU, Jie WANG, Lin WANG, Weidong LU, Qiyun SHAO, Jun FENG, Feng HE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, and specifically relates to the crystal form of the compound of formula (I) and a preparation method thereof. The new crystal form has good physical and chemical properties, thereby facilitating clinical treatments.
Claims18
-16. (canceled)
A crystalline form of a compound of formula (I):
- selected from the group consisting of crystalline form A and crystalline form B, wherein:
- the crystalline form A has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 8.610, 9.740, 13.903, 15.313, 16.354, 17.675, 17.879, 19.184, 19.905, 20.901, 21.365, 22.319 and 23.057;
- and
- the crystalline form B has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 4.60, 8.77, 9.90, 13.86, 15.45, 16.44, 17.74, 18.03, 19.31, 19.91, 21.07, 21.52, 22.48 and 23.22.
1 more element
Dependencies are inferred from the claim text.